{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-23-000068","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2023-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.861892+00:00","generated_at":"2026-06-10T10:48:23.754825+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Entrada doses first participant in Phase 1 trial of ENTR-601-44 for Duchenne MD","bullets":["First participant dosed in Phase 1 trial of ENTR-601-44 for DMD patients amenable to exon 44 skipping.","Trial conducted in UK; targets ~40 healthy male volunteers; endpoints include safety, PK, and target engagement.","Data from the Phase 1 trial expected in the second half of 2024.","Initiation marks Entrada's transition into a clinical-stage company."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-23-000068","json":"https://secwatch.observer/filing/0001689375-23-000068.json","markdown":"https://secwatch.observer/filing/0001689375-23-000068.md","text":"https://secwatch.observer/filing/0001689375-23-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000068/0001689375-23-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000068/trda-20230921.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T10:48:23.754825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}